Lenalidomide Based Immunotherapy in the Treatment of DLBCL
This study is to evaluate the efficacy related molecular biomarker of Lenalidomide plus RCHOP or RICE in the treatment of de novo or Refractory and Relapsed DLBCL patients
Diffuse Large B Cell Lymphoma
DRUG: Lenalidomide 25mg
Complete response rate, 12 weeks
Progression free survival rate, 1 year|Overall survival rate, 1 year|Overall response rate, 12 weeks
This study is to evaluate the efficacy related molecular biomarker of Lenalidomide plus RCHOP or RICE in the treatment of de novo or Refractory and Relapsed DLBCL patients